Sado Island in Japan is an area with low antimicrobial pressure. A total of 41 communityonset methicillin-resistant Staphylococcus aureus (MRSA) isolates were obtained from pediatric outpatients and healthy children between August 2009 and January 2012, and genotyping and antimicrobial susceptibility testing of the MRSA isolates were performed. Additionally, the sources of MRSA isolated from healthy 1-month-old neonates were assessed. All isolates were negative for the Panton-Valentine leukocidin genes. Our data showed a lower prevalence of staphylococcal cassette chromosome (SCC)mecII on Sado Island (31.7z in total and 46.7z in healthy carriage) than that in the other areas of Japan, suggesting that a low level of antimicrobial use may be related to a low SCCmecII carriage rate in the community. To our knowledge, this is the first report of sequence type (ST)81/SCCmecIVg strains as well as the novel ST strain (ST2180/SCCmecIVa) in Japan. In addition, we detected an arginine catabolic mobile element (ACME)-arcA-positive ST764/SCCmecIIa clone that could disseminate successfully in the community. Intrafamilial transmission was observed in neonates identified with the SCCmecIV MRSA strains, and these strains were genetically typed as community-associated MRSA; the transmission routes of the remaining SCCmecIIa MRSA (genetically typed as healthcare-associated MRSA) strains could not be defined. In this study, we have shown that multiple MRSA strains can circulate in a community even under low antimicrobial pressure.
INTRODUCTION
Staphylococcus aureus colonizes the human nasal mucosa and other body sites and can cause a variety of infections. Since 1961, methicillin-resistant S. aureus (MRSA) has been recognized as a nosocomial pathogen, i.e., the so-called healthcare-associated MRSA (HA-MRSA). In addition, community-associated MRSA (CA-MRSA), which often harbors genes for Panton-Valentine leukocidin (PVL), has been a major concern worldwide since the late 1990s (1) . CA-MRSA typically causes skin and soft tissue infections (SSTIs) and severe systemic infections. Because CA-MRSA mainly affects healthy children and young adults (1) , it is important to understand the types of infections it can cause in these populations.
In general, the MRSA classification is based on the epidemiological background, clinical features, and genetic analysis (1) . CA-MRSA is primarily defined as MRSA isolated from outpatients with no history of hospitalization within the previous year and from those who presented with no other established risk factors for MRSA infections, such as surgery, residence in a longterm care facility, dialysis, or indwelling percutaneous medical devices and catheters (1) (2) (3) .
CA-MRSA typically harbors smaller staphylococcal cassette chromosome mec (SCCmec) elements (SCCmecIV and V) that confer resistance to a few antimicrobials. On the other hand, HA-MRSA typically harbors larger SCCmec elements (SCCmecI, II, and III) that confer resistance to many antibacterial agents. It was generally accepted that lower antimicrobial pressure in the community correlates with smaller SCCmec elements (SCCmecIV and V) (1) . Nonetheless, MRSA with SCCmecIV or V (genotyped as CA-MRSA) have been identified in healthcare settings, and MRSA with SCCmecI, II, or III (genotyped as HA-MRSA) are known to circulate in the community. Therefore, the relationship to antimicrobial pressure and SCCmec is still unclear. Hence, judging the antimicrobial resistance patterns of MRSA based on medical history alone is difficult.
More recently, MRSA has been classified simply as community-onset MRSA (CO-MRSA) if the infection is confirmed 48 h or more before hospital admission (1) . Knowledge of the molecular characteristics and genotypes of CO-MRSA, particularly the antimicrobial resistance patterns, is essential for controlling its spread.
Molecular typing of MRSA includes multilocus sequence typing (MLST) (4), SCCmec typing (5, 6) , coagulase typing, and the carriage of PVL genes (7) . In Japan, the New York/Japan MRSA clone belonging to sequence type (ST)5 and possessing the SCCmecII is predominant among both inpatients and outpatients, followed by other minor STs, such as ST8, ST88, ST89, and ST91 with the SCCmecIV, which are primarily associated with SSTIs (8) . These MRSA isolates are mainly PVL negative. Further, genotyping of the other S. aureus genes such as the protein A gene (spa), accessory gene regulator gene (agr), and arcA gene within the arginine catabolic mobile element (ACME) is useful for characterizing MRSA. The ACME-arcA gene was shown to play a key role in S. aureus colonization in humans as well as in its spread in the community (9) .
Sado Island of Japan, which is located 60 km off the Japanese mainland, has a population of approximately 63,000, of whom 7,600 (12.1z) are aged 0-15 years. Since 2002, we have been conducting a series of intervention programs on the appropriate use of antimicrobials for children. Hence, the island is an area with low antimicrobial pressure, with 45-75 antimicrobial prescriptions per 1,000 clinic visits among children (routine health checkups and immunization visits were excluded) during 2002-2010 (10) (11) (12) . The ratio of antimicrobial agents in penicillins, cephalosporins, and macrolides was approximately 1:1:2, respectively (11) . There are only 5 pediatricians on the island: 3 at the Sado General Hospital and 2 at the Ryotsu Hospital. Thus, the treatment of almost all pediatric patients is restricted to these hospitals. The total number of pediatric outpatients with acute diseases was estimated to be 18,000 per year on Sado Island. We previously reported that the prevalence of MRSA among pediatric outpatients at the Sado General Hospital was 7.9z (14 MRSA isolates were identified from 177 S. aureus isolates) in 2010 (12) . No deaths of pediatric patients related to S. aureus have been recorded on the island in the past decade. Because of the limited movement of people (particularly among children) between Sado Island and the Japanese mainland, the island can be considered as an appropriate environment for investigating the diversity of S. aureus genotypes in an environment with low antimicrobial pressure.
MATERIALS AND METHODS
Clinical isolates: MRSA isolates were collected from outpatients aged 0-15 years between August 2009 and January 2012 at the Sado General Hospital and the Ryotsu Hospital.
In addition, MRSA isolates were collected from nasal mucosa samples obtained from healthy children aged 1 month, 4 months, 7 months, 10 months, 18 months, and 3 years at health checkups between March 2008 and January 2012 as part of the surveillance program on Sado Island (10, 11, 13) . Any healthy subject identified with MRSA was excluded from the next screening. Each subject's medical information, such as MRSA isolation site, previous hospitalization, and antimicrobial usage, was obtained from the medical records and by questionnaires.
Antimicrobial susceptibility testing: Antimicrobial susceptibilities of the MRSA isolates were determined by commercially available MIC panels (MICroScan Pos Combo 3.2J or 3.3J; Siemens Healthcare Diagnostics Inc., Deerfield, Ill., USA) using the microdilution broth method. MICs were categorized as susceptible, intermediate, or resistant according to the guidelines issued by the Clinical and Laboratory Standards Institute (14) .
The following antimicrobial agents were tested: ampicillin (AMP), oxacillin (OXA), gentamicin (GEM), erythromycin (ERY), clindamycin (CLI), inducible resistance of clindamycin (I-CLI), minocycline (MINO), fosfomycin (FOF), arbekacin, trimethoprim/sulfamethoxazole, teicoplanin, and vancomycin. Molecular analysis: Chromosomal DNA was extracted from the MRSA isolates using a High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany). For MLST (ST) and clonal complex (CC) analysis, the allelic profile of the MRSA isolates was obtained by sequencing the internal fragments of the 7 housekeeping genes described on the MLST website (4). The spa type was determined using the public spa-type database (http://spaserver2.ridom.de/ index.shtml) as previously described (15) . The SCCmec types (I to V) were analyzed by polymerase chain reaction (PCR) targeting the mec, ccr complexes and junk regions (5, 6) . The subtypes in SCCmecII, III, and IV were then determined by the reported primers (5, 6, 16, 17) . In addition, the PVL genes were analyzed by PCR, as previously described (7) . Coagulase types (I to VIII) were determined using a staphylococcal coagulase antiserum kit (Denka Seiken, Tokyo, Japan) according to the manufacturer's instructions. The ACME-arcA gene (9) and agr allele group (18, 19) were detected by PCR assay using the reported primers, as previously described.
Sources of MRSA isolates from 1-month-old neonates: To assess the sources of MRSA isolates between February 2011 and January 2012 among healthy 1month-old neonates, anterior nare swabs were collected twice (June and December 2011) from all healthcare workers working in the field of infant care at the Sado General Hospital, the only hospital in Sado Island with a maternity ward. Additionally, environmental cultures from infant bassinets, stethoscopes, infant incubators, doorknobs, and the floor of the baby care room were obtained. In addition, immediately after the detection of MRSA in the 1-month-old neonates, anterior nare swabs were collected from their family members.
Ethics statement: Written informed consent was obtained from the guardians of all children in this study from whom MRSA isolates were obtained. Further, informed consent was obtained from the healthcare workers and the family members screened in this study. The study protocol was approved by the Ethics Committee at the Sado General Hospital.
RESULTS
Clinical isolates: During the study period, 3,939 samples from pediatric outpatients and 1,333 samples from healthy children were analyzed. Hence, 26 MRSA isolates were obtained from pediatric outpatients, and 15 MRSA isolates were obtained from healthy children ( Table 1 ). All 41 MRSA isolates were collected 48 h or 
Genetically HA/CA  HA  HA  HA  CA  HA  CA  CA  CA  CA  CA  CA   agr  II  II  II  I  I  III  III  I 1)  IV  III  III  ACME-arcA  --＋  --------Coagulase  II  II  II  III  III  I  I  VII  V  VII  I  Resistance 2 more prior to hospital admission and they were thus classified as CO-MRSA (1). In total, 9 subjects had a history of hospitalization within the previous year. Of the 41 CO-MRSA isolates, 26 were collected from the nasal mucosa (11 upper/lower respiratory tract infections and 15 healthy carriage), 11 from skin lesions (bullous impetigo), 2 from ear discharge (acute otitis media), and 2 from the urine (urinary tract infection). However, some of these isolates could be considered as simply arising from colonization or contamination. Actually, other predominant bacterial pathogens were isolated from the urine samples, while no other bacterial pathogens were isolated from the ear discharges. MRSA was not detected in the blood during the study period. The 15 MRSA isolates obtained from healthy subjects consisted of 9 isolates obtained at the 1-month (out of 320 screened subjects), 1 at 4-month (out of 205 subjects), 1 at 7-month (out of 115 subjects), 2 at 10-to 11month (out of 113 subjects), 1 at 1-year (out of 324 subjects), and 1 at 3-year (out of 256 subjects) health checkups. There were no subsequent infections among these healthy carriers. Antimicrobial susceptibility testing: The antimicrobial susceptibilities of the MRSA isolates are summarized in Table 1 . Of the 41 subjects carrying MRSA, 11 (26.8z) received antimicrobial therapy within 3 months. Although several antimicrobials such as AMP, clarithromycin (CLR), and cephalosporins were prescribed before MRSA isolation, the MRSA isolates were found to be resistant to these agents based on the susceptibility testing. However, 30 (73.2z) subjects did not receive antimicrobial therapy within 3 months; thus, there was no relation between the antimicrobial agents and MRSA types on an individual level. When the types of antimicrobial agents were compared, no difference was observed between the total and pre-isolation prescriptions.
None of the 1-month-old neonates, who were positive for MRSA, received antimicrobial therapy before sample collection. The isolates with SCCmecIIa exhibited multiple-drug resistance to AMP, OXA, GEM, ERY, CLI, MINO, and FOF, while those with SCCmecIV (subtype a, c, g, and l) showed resistance to fewer antimicrobials agents. Of the 41 MRSA isolates in this study, GEM resistance was detected in 68.3z of isolates, ERY resistance in 68.3z, CLI resistance in 58.5z (including I-CLI in 19.5z), MINO resistance in 31.7z, and FOF resistance in 34.1z. No resistance was observed for arbekacin, trimethoprim/sulfamethoxazole, teicoplanin, or vancomycin.
Molecular characterization of CA-MRSA: Characteristics of the 41 CO-MRSA strains are summarized in Table 1 . All 41 MRSA isolates analyzed in this study were PVL-negative, but were genetically diverse. The isolates could be classified into 11 strains according to the ST and SCCmec type as follows: ST5/SCCmecIIa (n ＝ 7) and SCCmecIVc (n ＝ 1), ST764/SCCmecIIa (n ＝ 6), ST8/SCCmecIVl (n ＝ 8) and SCCmecI (n ＝ 1), ST92/SCCmecIVa (n ＝ 5), ST509 with nontypeable SCCmec (n ＝ 2), ST59/SCCmecIVa (n ＝ 4), ST121/ SCCmecV (n ＝ 4), ST81/SCCmecIVg (n ＝ 2), and ST2180/SCCmecIVa (n ＝ 1).
The spa gene typing revealed greater diversity than ST ( Table 1 ). A total of 14 different spa types were observed, while 9 STs were identified. Of the 41 CO-MRSA isolates, 6 MRSA isolates (14.6z) belonging to ST764/SCCmecIIa harbored the ACME-arcA gene.
The isolates (n ＝ 15) obtained from healthy subjects at the health checkups belonged to the following 7 strains; ST5/SCCmecIIa (n ＝ 4), ST764/SCCmecIIa (n ＝ 3), ST8/SCCmecIVl (n ＝ 4), ST8/SCCmecI (n ＝ 1), nontypeable ST509/SCCmec (n ＝ 1), ST59/ SCCmecIVa (n ＝ 1), and ST2180/SCCmecIVa (n ＝ 1). Of these 15 isolates, 9 were obtained from 1-month-old neonates ( Table 2 ). These isolates belonged to the ST5/ SCCmecIIa (n ＝ 2), ST764/SCCmecIIa (n ＝ 3), ST8/ SCCmecIVl (n ＝ 3), and ST2180/SCCmecIVa (n ＝ 1) strains.
Sources of MRSA isolates obtained from the 1month-old neonates: A total of 320 anterior nare swabs were collected from healthy 1-month-old neonates (participation rate, 99.7z). All healthcare workers (3 pediatricians, 3 obstetricians, and 23 nurses) were screened for nasal carriage twice in June 2011 and December 2011, because 320 subjects screened at the 1month health checkup were born in 2011. All swabs obtained from the infant care staff in our hospital were negative for MRSA. Further, environmental cultures did not show any evidence of MRSA dissemination. A total of 49 family members (9 mothers, 8 fathers, 15 siblings, and 17 relatives) of the 1-month-old neonates with MRSA were screened for nasal carriage ( Table 2) . Only 1 family member (SADO-R1's father) refused. MRSA was detected in family members of 4 of the 9 1-month-old neonates who were positive for MRSA (SADO-R15, -R16, -R17, and -R41), suggesting intrafamilial transmission of MRSA (Table 2) . These same household MRSA isolates were identical to the MRSA isolates from the respective neonates (ST8/spa-t1767/SCCmecIVl and ST2180/spa-t1784/ SCCmecIVa).
DISCUSSION
The antimicrobial prescription rate among children in the Sado General Hospital (45-75 per 1,000 clinic visits during 2002-2010) was found to be lower than the previously reported rates on the Japanese mainland (256 per 1,000 clinic visits in 2007; P º 0.001); this might result in the lower prevalence of MRSA (12) . Our data showed a lower prevalence of SCCmecII on Sado Island (31.7z in total and 46.7z in healthy carriage) than that (68z-83z) in the other areas of Japan (Hokkaido, Miyagi, Kyoto, and Saga) (20, 21) . These data suggested that a low level of antimicrobial use may be related to the low SCCmecII carriage rate in the community.
We identified 5 other minor clones in addition to the CC5/SCCmecIIa, CC8/SCCmecIVl, and CC509/ SCCmecIVa-nontypeable clones that are commonly detected in Japan as disease-causing strains. Of these 5 minor clones, 3 strains (ST121/SCCmecV, ST59/ SCCmecIVa, and ST5/SCCmecIVc) are known to be rare in Japan. To the best of our knowledge, the ST121 clone has mainly been reported as a PVL-positive methicillin-susceptible S. aureus clone (21-23), while there have been only a few reports of ST121 MRSA clones isolated in Japan, China, and Cambodia (24, 25) . In addition, to our knowledge, we report the first detection of the ST81/SCCmecIVg strain in Japan. Berglund et al. (16) and Hisata et al. (26) previously reported that SCCmecIVg strains belonged to ST1, ST30, ST45, ST59, ST88, and ST140 in Sweden and Japan. In our study, the SCCmecIVg strain was found to belong to ST81, suggesting that SCCmecIVg may show different molecular characteristics according to the country of circulation. Furthermore, a novel ST of CC1 (ST2180/ SCCmecIVa) was isolated. ST2180 is a single-locus (yqiL) variant of ST1.
The ST764/SCCmecIIa MRSA clone, a single-locus variant of the New York/Japan clone, was first isolated from bacteremia in an inpatient on Sado Island (27) and is now spreading not only in hospitals but also throughout the community as a colonization and disease-causing strain (8, 28) . This clone, a genetically typed HA-MRSA clone conferring resistance to many antibacterial agents and with a higher ability to adapt to the community in a manner similar to CA-MRSA (28), was considered to be an emerging HA/CA-hybrid-type clone (8) . In the present study, we identified the ACME-arcApositive ST764/SCCmecIIa clone for the first time. The ACME-arcA gene has been associated with prolonged survival of S. aureus on the skin (9); therefore, the ST764/SCCmecIIa MRSA clone could disseminate successfully in the community. The ACME-arcA gene and its gene cluster were originally associated with SSTIs (9). Of the 6 ACME-arcA-positive isolates obtained in this study, 3 were from 1-month-old healthy infants, 2 from patients with acute otitis media without other bacterial pathogens, and 1 from a patient with SSTI. The 2 patients with acute otitis media had recurrent episodes of the condition, suggesting that the ACME-arcA gene may also play a role in acute otitis media.
In this study, we found 9 cases of 1-month-old neonates-positive for MRSA due to ST5/SCCmecIIa, ST764/SCCmecIIa, ST8/SCCmecIVl, or ST2180/ SCCmecIVa. Interestingly, intrafamilial transmission was involved in neonates with the SCCmecIV MRSA strains (ST8/SCCmecIVl and ST2180/SCCmecIVa), and the strains were genetically typed as CA-MRSA; the transmission routes of the SCCmecIIa MRSA strains (ST5/SCCmecIIa and ST764/SCCmecIIa, genetically typed as HA-MRSA) could not be defined. Our data suggested that genetically typed CA-MRSA can disseminate even in a community with controlled antimicrobial use.
In conclusion, we show that multiple MRSA strains can circulate in a community even under low antimicrobial pressure. The cases of MRSA detected in healthy neonates highlight the importance of continued monitoring of this population in order to better understand the effects of MRSA carriage on their health.
